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Abstract Resistin, a new adipocytokine, is expressed in hu-
man, rat and mouse adipose tissue. Its putative role as a medi-
ator of insulin resistance is controversial. We hypothesized that
resistin, in common with leptin, has multiple roles in non-adi-
pose tissues. Using reverse transcription polymerase chain reac-
tion (RT-PCR) we show that the resistin gene (Retn) is ex-
pressed in mouse brain (hypothalamus and cortex) and
pituitary gland. Immunohistochemistry revealed resistin protein
in the arcuate nucleus and pituitary gland. Semi-quantitative
RT-PCR analysis indicated that Retn mRNA is developmen-
tally regulated in the pituitary. Expression was lowest at birth,
increased abruptly between postnatal days 14 and 25 (four-fold;
P6 0.001), and declined thereafter. This peak in pituitary Retn
mRNA was una¡ected by early weaning but was abolished
by neonatal treatment with monosodium glutamate, suggesting
that the basal hypothalamus regulates pituitary Retn. Although
the role(s) of endogenous resistin in mouse brain and pituitary
remains to be determined, it may be distinct from its controver-
sial involvement in insulin resistance. Our data suggest that
local resistin expression could have functional implications
during prepubertal maturation of the hypothalamic^pituitary
system. 3 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Type 2 diabetes is characterized by insulin resistance in
certain peripheral tissues and is often associated with obesity.
However, the relationship between obesity and insulin resis-
tance is not understood. A new adipocyte-derived circulating
hormone, resistin [1], was suggested to induce insulin resis-
tance. Resistin is part of a multigene family of cysteine-rich
proteins, termed RELMs or FIZZ proteins [2]. To date three
members of this family have been described, all secreted pro-
teins with unique tissue distributions [2,3]. Resistin is ex-
pressed and secreted from mouse [1] and rat [4] fat, and di¡er-
entiated 3T3L1 adipocytes [1]. Low level expression was also
noted in rodent mammary gland [1]. Human resistin has been
reported in fat [1,5,6] and in primary preadipocytes [7,8]
though this is controversial [9,10].
Adipocyte-derived resistin was proposed to antagonize the
actions of insulin [1,11], providing a putative hormonal link
between obesity and diabetes. Resistin treatment impaired
glucose tolerance whereas immunoneutralization improved in-
sulin action. Serum resistin levels were down-regulated by
rosiglitazone, an anti-diabetic drug which enhances insulin
sensitivity. These ¢ndings were subsequently con¢rmed in
db/db mice [12]. However, other reports challenge the role
of resistin as a mediator of insulin resistance, particularly in
humans. No di¡erences in adipocyte Retn expression were
observed between normal, insulin-resistant and type 2 diabetic
patients [9], and Retn mRNA was undetectable in adipocytes
from an insulin-resistant patient [10]. Insulin increased Retn
gene expression in streptozotocin-diabetic mice [4] and Retn
expression was increased by rosiglitazone in ob/ob mice and
Zucker fa/fa rats [13]. A substantial reduction in Retn mRNA
levels in 3T3L1 adipocytes treated with insulin was also ob-
served [14].
We hypothesized that resistin could be implicated in phys-
iological systems which are distinct from those involving adi-
pose tissue. For example, Retn expression is in£uenced by
several factors which are not restricted to control of adipose
tissue, including: TNF-K [15], L-adrenergic agonists [16] and
testosterone [17]. Holcomb et al. [3] suggested that the resis-
tin-like molecule FIZZ 1 modulates the function of sympa-
thetic neurons. Another adipocytokine, leptin, is also made in
brain and pituitary [18^20]. Since adipose Retn expression is
regulated via the peroxisome proliferator-activated receptor
gamma, which is also localized to the brain [21], the present
study was undertaken to determine whether resistin was ex-
pressed in the developing brain and pituitary of the mouse.
2. Methods
2.1. Mice
Adult CD1 and C57BL 6 (female; 40 days old) mice were obtained
from Charles River Breeding Farms (Quebec, Canada), maintained
under a photoperiod of 14 h light:10 h darkness (lights on: 0700 h)
and given free access to Purina Rat Chow and drinking water. The
experimental protocol was reviewed and approved by the Dalhousie
University Committee on Laboratory Animals. Mice were killed by
decapitation and samples of frontal cerebral cortex, basal hypothal-
amus and visceral/gonadal fat were dissected and frozen in liquid
nitrogen. The pituitary gland was removed intact (anterior plus pos-
terior). Each n value represents tissue pooled from three to four mice.
For the developmental study, female CD1 mice were received with
their mothers, on postnatal day (PD) 2. Pups were weighed and killed
by decapitation on PDs 3, 7, 14, 18, 21, 25, 28 and 40. Intact pituitary
glands and hypothalami were collected for analysis of resistin mRNA
levels. Newborn CD1 pups were also treated with monosodium glu-
tamate (MSG; 4 mg/g; s.c.; Sigma) on PDs 3 and 4. Control mice
received saline. Pups remained with their mothers and were killed by
decapitation on PD 21. Intact pituitaries and visceral fat were col-
lected for reverse transcription polymerase chain reaction (RT-PCR)
0014-5793 / 02 / $22.00 I 2002 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 2 ) 0 3 1 0 8 - 3
*Corresponding author. Fax: (1)-902-4707192.
E-mail address: mwilk@is.dal.ca (M. Wilkinson).
FEBS 26366 16-8-02
FEBS 26366FEBS Letters 526 (2002) 26^30
analysis. Each n value represents pooled tissue from a minimum of
four mice. Data were derived from two independent experiments.
2.2. RNA isolation and semi-quantitative RT-PCR analysis
Total RNA was isolated from brain and pituitary using the RNeasy
mini kit (Qiagen; Mississauga, ON) and from adipose tissue using
Trizol reagent (Gibco). The RNA was DNase treated using the
RNase-free DNase kit (Qiagen). RNA (1.75 Wg) was denatured at
65‡C for 5 min and reverse transcribed in a ¢nal volume of 30 Wl
using Omniscript reverse transcriptase (Qiagen) at 37‡C for 1 h. PCR
ampli¢cation was performed using two alternate sets of intron-span-
ning (278 bp, R1, and 330 bp, R2) resistin primers and HotStarTaq
DNA polymerase (Qiagen). The sequences of the primers are as fol-
lows: R1 forward, 5P-TTCCTTGTCCCTGAACTGCT-3P, reverse,
5P-TGCTGTCCAGTCTATCCTTG-3P and R2 forward, 5P-GCTGT-
GGGACAGGAGCTAATA-3P, reverse, 5P-GTCCCACGAGCCAC-
AGGCAGA-3P. The PCR reaction was performed as described pre-
viously [20]. Reactions were normalized by evaluating the level of
ampli¢cation of the 18S transcript using commercial primers (Classic
18S primers; Ambion, Austin, TX). For semi-quantitative analysis,
each sample was ampli¢ed within the exponential phase of the PCR
(pituitary: resistin, 30 PCR cycles; 18S 20^21 cycles). For each target
no ampli¢cation product was detected in the absence of reverse tran-
scriptase. PCR-ampli¢ed DNA was electrophoresed on 1.5% agarose
gels and visualized by ethidium bromide staining. Product yield was
determined using NIH Image (v.1.60) software. Data were expressed
as a ratio relative to 18S in arbitrary units.
2.3. Cloning and sequencing
Total RNA from hypothalamus and gonadal fat was reverse tran-
scribed and PCR-ampli¢ed as described above. Portions of the result-
ing PCR reaction were cloned into pGEM-T Easy (Promega, Madi-
son, WI) and transformed into Escherichia coli. Individual
transformants were sent for sequence analysis to the Dalhousie Uni-
versity^NRC Institute for Marine Biosciences Joint Laboratory (Hal-
ifax, NS).
2.4. Saline perfusion washout of blood cells
Male mice (approximately PD 40) were anesthetized with somnotol
(65 mg/kg; i.p.) and perfused with sterile saline (room temperature;
40 ml per mouse) to remove blood contamination from the brain and
pituitary. A second group was anesthetized but not perfused. Samples
of hypothalamus and pituitary glands were obtained as described (see
Section 2.1).
2.5. Immunohistochemistry
Resistin protein was detected in ¢xed tissue from brain and pitui-
tary gland (4% paraformaldehyde) [22] using a rabbit polyclonal anti-
serum (Phoenix Pharmaceuticals; # H-028-40; 1:12 000 (brain) or
1:1000 (pituitary).
2.6. Statistical analysis
Data were analyzed by Student’s t-test or analysis of variance with
Newman^Keuls post hoc test and are reported as meanSS.E.M.
3. Results
3.1. Retn mRNA is expressed in mouse brain and pituitary
Retn expression in mouse brain and pituitary was evaluated
in adult C57BL 6 and CD1 mice using RT-PCR analysis with
two alternate sets of resistin primers designed to span 278 and
330 bp of the cDNA. Products of the expected sizes were
reproducibly observed in fat, hypothalamus, cortex and whole
pituitary gland using both sets of primers in both strains of
mice (Fig. 1A). Retn expression was readily detectable even
after 30 cycles. No PCR product was detected using either set
of PCR primers in the negative control or in the absence of
reverse transcriptase. The 278 bp and 330 bp PCR amplicons
were cloned and sequence analysis indicated 100% homology
with the corresponding region of mouse resistin cDNA [1].
Since low level expression of resistin has been reported in
human monocytes [9,10], we compared Retn mRNA levels
in saline-perfused and non-perfused tissues. Our results indi-
cated that resistin expression was identical in both perfused
and non-perfused mouse brain and pituitary (Fig. 1B). Retn
expression in microdissected arcuate nuclei (ARCs) was com-
pared to expression in the remainder of the hypothalamus
using semi-quantitative RT-PCR analysis (278 bp primers).
Resistin expression was signi¢cantly higher (Vthree-fold;
n=4; P6 0.005) within the ARC compared to the remainder
of the hypothalamus (data not shown), consistent with the
immunolocalization of resistin protein (see Fig. 2).
3.2. Immunohistochemical localization of resistin
Resistin immunoreactivity was localized to scattered cell
bodies in the ARC, with additional small amounts present
in the ventrolateral ventromedial hypothalamus and in the
dorsal periventricular area (Fig. 2A,C). Resistin immunoreac-
tivity was also present in anterior and intermediate lobes of
the pituitary, but little staining was seen in posterior lobe (Fig.
2D). Staining was abolished by preadsorption of the antise-
rum with the immunizing peptide or by removal of the pri-
mary antiserum (Fig. 2B,E).
3.3. Developmental regulation of resistin mRNA in mouse
pituitary
Developmental changes in resistin mRNA levels were eval-
uated between PDs 3 and 40 in female CD1 mouse pituitary
and hypothalamus using semi-quantitative RT-PCR analysis.
For each tissue, ampli¢cation was performed within the ex-
ponential phase of the PCR reaction (pituitary 31 cycles, hy-
pothalamus 32 cycles). Retn mRNA was detected in the hy-
pothalamus and pituitary throughout neonatal development
(PDs 3^40), though age-dependent changes in Retn mRNA
levels were noted in the pituitary, where a peak in Retn ex-
pression was observed at PD 21 (non-weaned; Fig. 3A;
Vfour-fold between PDs 14 and 21; n=7; P6 0.001). A
Fig. 1. A: Retn expression in mouse brain and pituitary. RT-PCR
analysis of RNA isolated from the hypothalamus (HYP), cortex
(CTX), pituitary (PIT) and visceral fat of adult female C57BL6 and
CD1 mice using two alternate sets of intron-spanning Retn primers.
Sequence analysis of the 278 bp and 330 bp amplicons revealed
100% homology with the corresponding region of murine Retn
cDNA. B: RT-PCR analysis of Retn expression (278 bp) in the
brain and pituitary of adult male CD1 mice which had been per-
fused with sterile saline (40 ml) and from non-perfused control
mice.
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closer evaluation of the time interval surrounding this peak in
resistin expression revealed a gradual increase and decline
between PDs 14 and 28 with maximal levels between PDs
21 and 25 (Fig. 3B). We compared resistin expression in
mice which had been weaned for 6 and 24 h and in non-
weaned mice (PD 21). The increase in resistin expression at
PD 21 was una¡ected by weaning. By contrast, in the hypo-
thalamus, although resistin was expressed throughout postna-
tal development (PDs 3^40) no signi¢cant age-related di¡er-
ences were observed (data not shown).
To determine whether pituitary Retn expression was depen-
dent on an intact hypothalamus, the ARC was neurotoxically
lesioned with neonatal MSG treatment [22,23]. Semi-quanti-
tative analysis of Retn mRNA in pituitaries of PD 21 male
mice revealed a marked attenuation of resistin expression
(Fig. 4). In preliminary experiments, a similar e¡ect on pitui-
tary Retn expression was observed in female CD1 mice. Retn
expression in visceral fat (PD 21) was not a¡ected by neonatal
MSG treatment (data not shown).
4. Discussion
This study represents the ¢rst demonstration of resistin
mRNA expression in mouse brain and pituitary. In addition
to adipocytes, Retn mRNA was reported in rodent mammary
gland [1]. Holcomb et al. [3] detected Retn mRNA in several
Fig. 2. Immunolocalization of resistin in mouse brain and pituitary. Representative images of resistin immunoreactivity in coronal sections of
the ARC (A), dorsal periventricular region of the hypothalamus (C) and anterior pituitary (D) obtained from male CD1 mice perfusion-¢xed
with 4% paraformaldehyde. Note that immunoreactivity was abolished following removal of the primary antiserum (B,E). Scale bars are 100
Wm.
Fig. 3. Developmental regulation of Retn expression in mouse pitui-
tary. Intact pituitaries were collected from CD1 mice on PDs 3, 14,
21, 28 and 40 (A) or PDs 14, 18, 21, 25, and 28 (B) for RNA isola-
tion and semi-quantitative RT-PCR analysis of Retn expression.
Representative ethidium bromide-stained gels are shown. Cumulative
results (meanSS.E.M.) are shown. Numbers below standard error
bars represent n values. *P6 0.001; PD 21 vs PDs 3, 14, 28, 40.
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organs, though these data were not reported. Low level ex-
pression was also found in human monocytes [9,10], but in
our hands resistin was expressed equally in saline-perfused
and non-perfused mouse pituitary and hypothalamus, suggest-
ing that monocytes are not a signi¢cant source of resistin in
mouse pituitary and brain. Our results indicated that Retn
mRNA was localized to the ARC of the hypothalamus, and
immunohistochemistry con¢rmed the presence of resistin pro-
tein. At present the phenotype of these resistin-positive cells is
unknown, though the periventricular cells could be tanycytes
or astrocytes based on their appearance (Fig. 2). Positive
staining was also seen in the anterior and intermediate lobes
of the pituitary, con¢rming the strong Retn mRNA expres-
sion. The role of resistin in the hypothalamo^pituitary system
is unclear, but peripheral Retn mRNA and serum levels are
regulated by fasting/refeeding [1,4], insulin [1,4,13,14], testos-
terone [17] and in genetic models of obesity [1,13]. In future
experiments it will be important to determine the e¡ects of
each of these factors on brain and pituitary resistin expres-
sion.
The signi¢cance of the developmental rise in Retn mRNA
levels between PDs 14 and 21 in mouse pituitary is unknown.
The peak in pituitary resistin expression occurs over a 2 week
period, just prior to puberty, between PDs 14 and 28, with
maximal levels between PDs 21 and 25. By comparison, hy-
pothalamic levels remained constant throughout development.
The increase in Retn expression appeared to be coincident
with the time of weaning. However, our results do not support
a direct e¡ect of weaning since a similar increase was observed
in both weaned and non-weaned mice. In further studies we
determined whether pituitary Retn mRNA was dependent
upon an intact hypothalamus. Treatment of neonatal rodents
with MSG is an accepted approach to selectively ablate the
ARC of the hypothalamus [24] and to in£uence developmen-
tal changes in the pituitary gland [25]. Our data show that
pituitary Retn expression is dependent upon an intact hypo-
thalamus, though it remains to be determined which pituitary
cell type(s) express resistin protein. It may also be signi¢cant
that MSG-treated mice become obese as adults and show
hyperglycemia and hyperinsulinemia, although surprisingly re-
sistin expression in visceral fat was una¡ected [26].
We have recently reported developmental regulation of lep-
tin mRNA in rat pituitary, where expression was maximal
during PDs 7^14 and fell sharply by PD 22. The role of
endogenous leptin in the pituitary has not been determined,
but our data, together with those for resistin, suggest that
local adipocytokine expression may have functional signi¢-
cance in the development of the brain^pituitary system. As
with leptin, additional unexpected roles for resistin are possi-
ble. For example, in addition to its well characterized role as a
satiety factor, leptin has been reported to be important for
neuronal maturation [20,27,28]. Considering the strong asso-
ciation of obesity and diabetes, it will be important to deter-
mine whether resistin and leptin co-localize in the brain and
pituitary and to extend these studies to other species.
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